Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1995-02-23
1999-03-30
Harrison, Robert H.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
424451, 514691, 514729, 514962, A61K 31045, A61K 31075, A61K 31095, A61K 3112
Patent
active
058890491
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The present invention relates to the use of saturated monocyclic or bicyclic terpenes for the treatment of inflammatory diseases. It is particularly concerned with the use of saturated monocyclic terpenes for the treatment of steroid-requiring inflammatory diseases exacerbated by infection, such as, for example, bronchial asthma.
Acute and/or chronic inflammatory or acute allergic and/or chronic allergic inflammatory lesions are characterized by inflammatory infiltration of various organ systems by monocytes/macrophages, eosinophils, basophils and neutrophils, granulocytes, mast cells and thrombocytes. The degree of inflammatory activity correlates with the influence of these inflammatory cells in organ tissue, which causes damage to the organ concerned. These processes are a familiar feature in primary inflammatory diseases of the airways, the intestine and the articular cartilage in rheumatoid arthritis. Since the primary cause triggering most chronic inflammatory diseases is not known, these diseases can only be alleviated by nonspecific suppression of the inflammation stimulus. In an appropriate genetic predisposition or in the presence of environmental noxae, the reaction of the body to the exogenous noxae can be inhibited prophylactically by nonspecific suppression of the inflammation stimulus before the manifestation of disease symptoms.
At the level of the cell, the further migration of inflammatory cells into an area of inflammation can be reduced by inhibiting chemotactic factors. This leads to the inflammatory activity subsiding with decline of the morphological and functional disorders of the organ system concerned, an effect which is typically mediated by immunosuppressants, e.g. corticosteroids. This group of agents is known to have an activity profile which comprises a strong anti-inflammatory effect, but is only poorly tolerated since it causes severe side effects, namely osteoporosis, gastric and duodenal ulcers, steroid purpura or lymphopenia.
Corticosteroids are known to inhibit the activity of phospholipase and cytokines in various inflammatory cells. After inhibition of the phospholipase activity, the release of arachidonic acid from the phospholipid stores in the cell membrane is inhibited. Arachidonic acid is known to be an important substrate for the formation of various mediators.
The actual inhibitory action on inflammation is mediated by inhibition of cytokine production and via a reduced production of arachidonic acid. The latter is the precursor for the formation of potent chemotactic metabolites of the 5-lipoxygenase pathway (leukotrienes) and the cyclo-oxygenase pathway (prostaglandins, thromboxane) with a constrictor action on smooth muscle cells. Owing to the persistent suppression, especially of mediators of the 5-lipoxygenase metabolic pathway, the need for systemically active corticosteroids is therefore reduced and the activity of the inflammatory process is suppressed with diminishing infiltration with inflammatory cells.
For this reason, the disease course of various acute, chronic or allergic inflammations can be favorably influenced by nonspecific inhibition of inflammation.
SUMMARY OF THE INVENTION
The subject matter of the present invention is the use of saturated monocyclic or bicyclic terpenes, especially those of a menthane, terpene alcohol, thiol, ketone or carane, pinane, bornane basic structure or a corresponding oxo compound of the bicyclic terpene structures (1,8-oxidomenthane and menthol are especially preferred) for suppression of the release of arachidonic acid, mediators of inflammation and cytokines.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a graph showing the effects of cineol on the FEV.sub.1 in patients with asthma;
FIG. 2 is a graph showing the effects of cineol on the airway resistance of patients with asthma;
FIGS. 3 and 4 are graphs showing the effects of 1,8-cineol on LTB.sub.4 production in patients with asthma in vivo;
FIG. 5 is a graph showing the inhibition of monocyte LTB.sub.4 production in normal su
REFERENCES:
patent: 4103019 (1978-07-01), Mira
patent: 4775667 (1988-10-01), Saitoh et al.
patent: 5120538 (1992-06-01), Oei
patent: 5294443 (1994-03-01), Lipsky et al.
patent: 5322689 (1994-06-01), Hughes et al.
patent: 5338758 (1994-08-01), Chu et al.
patent: 5420162 (1995-05-01), Blumberg et al.
patent: 5464754 (1995-11-01), Dennis et al.
patent: 5527890 (1996-06-01), Rao et al.
patent: 5580562 (1996-12-01), Lipsky et al.
patent: 5616458 (1997-04-01), Lipsky et al.
patent: 5665386 (1997-09-01), Benet et al.
Cousergue, J.L., Allergies to Terpene Products in Asthmaties., Revue Francese D'Allergolgie 5, 3 Jul.-Sep. 1965, pp. 160-168 (Full Translated Copy).
Cousergue, J.L. Allergy to Terpene Products in Asthmatic Subjects (Occupational Allergies Excluded). Moroccan Study. Rev-Fr-Allergol. vol. 5, No. 3, pp. 160-168 (1965). Full Translation.
Wagner, H., et al. in-Vitro Inhibition of Prostaglandin Biosynthesis by Essential Oils and Phenolic Compounds. Planta Medica. No. 3, pp. 184-187. 1986. Full Translation.
Grimm, H. Antiobstruktive Wirksamkeit von Cineol Bei Atemwegserkrankungen. Therapiewoche, vol. 37, No. 45, pp. 4306-4311. (1987). Full Translation.
Flower, R.J., et al. Anti-inflammatory Steroids Induce Biosynthesis of Phospholipase A2 Inhibitor Which Prevents Prostaglandin Generation. Nature, vol. 278, pp. 456-459. 29 Mar. 1979.
Fisher, D.A. Exercise-Induced Bronchoconstriction Related to Isotretinoin Therapy. J-Am-Acad-Dermatol. vol. 13, No. 3, p. 524. Sep. 1985.
Grimm, H. Antiobstruktive Wirksamkeit von Cineol Bei Atemwergekrankungen. Therapiewoche, vol. 37, No. 45, pp. 4306-4311. (1987).
Fiedler-Nagy, C., et al. Comparative Study of Natural and Synthetic Retinoids as Inhibitors of Arachidonic Acid Release and Metabolism in Rat Peritoneal Macrophages. Dermatogica.
Vol. 175: Supplement 1, pp. 81-92. (1987).
Fawzy, A.A., et al. Inhibition Of Human Non-Pancreatic Phospholipases A2 by Retinoids and Flavonoids. Mechanism of Action. Agents & Actions. 25(3-4) pp. 394-400. (1988).
Eccles, R., et al., The Effects of Oral Administration of (-) Menthol on Nasal Resistance to Airflow & Nasal Sensation of Airflow in Subjects Suffering from Nasal Congestion.
Associated with the Common Cold. J. Pharm. Pharmacol., vol. 42, pp. 652-654. (1990).
Hope et al. Retinoids Inhibit Phoapholipase A2 in Human Synovial Fluid and Arachidonic Acid Release From Rat Peritoneal Macrophages. Inflammation, 14(5), pp. 543-549. (1990).
Trampsch, K.M., et al. Novel Inhibitor of Phospholipase A2 With Topical Anti-Inflammatory Activity. Biochemical and Biophysical Research Communications. 189(1) pp. 272-279. Nov. 1992.
LandOfFree
Use of terpene compounds for reduced release of arachidonic acid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of terpene compounds for reduced release of arachidonic acid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of terpene compounds for reduced release of arachidonic acid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1215580